Amgen Inc's Next Blockbuster Drug Delivers

On Thursday's edition of Market Checkup, The Motley Fool's health-care focused show for investors, Fool health-care analyst David Williamson sheds some light on what's driving the biggest movers in the health-care space today.

Amgen has just released phase 3 data for its PCSK9 drug, AMG 145, and the results are impressive. Drugs that aim to block the PCSK9 enzyme have the potential to lower cholesterol levels in patients, and AMG 145 has met both of its phase 3 endpoints while remaining relatively well-tolerated by the trial patients. In a phase 2 trial, AMG 145, also called evolocumab, led to a 51% reduction in LDL levels, which rose to a 63% reduction when combined with a statin. David emphasizes just how much more effective this is than the currently available treatments on the market, and discusses why this drug could be a multi-billion dollar blockbuster. He also discusses some of Amgen's competitors, and tells investors who else could be affected as this drug potentially makes its way to market.

More great biotech investing ideas?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

The article Amgen Inc's Next Blockbuster Drug Delivers originally appeared on

David Williamson owns shares of Merck and Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story